Cumberland Pharmaceuticals Inc.
NASDAQ:CPIXDrug Manufacturers - Specialty & Generic
-$0.06 today
- Market cap
- $98.52M
- Beta
- 0.10
- P/E (TTM)
- -11.5
- EPS (TTM)
- -$0.48
Volume 0.16M
Average 0.97M
CPIX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cumberland Pharmaceuticals Inc.NASDAQ: CPIX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $1.46M rose 12.6% year over year, behind the +15.7% change in trailing-twelve-month research & development. Sequentially, it fell 5.9% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.
Context
- Research & development amounted to 12.5% of revenue in FY2025, down 0.2 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +12.6% toward the trailing-twelve-month pace of +15.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 5.57M USD
- Year-over-year change
- +15.6%
- 4-year CAGR
- -0.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.57M | +15.6% |
| FY2024 | 2024-12-31 | 4.82M | -17.4% |
| FY2023 | 2023-12-31 | 5.83M | -12.8% |
| FY2022 | 2022-12-31 | 6.69M | +17.7% |
| FY2021 | 2021-12-31 | 5.68M | — |
Research & Development vs competitors
How CPIX compares with its peers on the latest reported figures
- CPIX's LTM Mar 2026 research & development of $5.73M is the 3rd highest of the 4 companies compared; the peer median is $9.98M.
- Its year-over-year change of +15.7% is the highest of 4, against a peer median of -13.6%.
- Research & development amounts to 13.7% of revenue for CPIX, versus a peer median of 60.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $15.03M | -13.6% | -42.3% | 56.6% | |
| LTM Mar 2026 | $9.98M | -34.1% | +10.2% | — | |
| LTM Mar 2026 | $5.73M | +15.7% | -5.9% | 13.7% | |
| LTM Mar 2026 | $1.91M | -5.1% | -21.8% | 64.3% | |
| Peer median (excluding CPIX) | $9.98M | -13.6% | -21.8% | 60.5% | |
Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 35.99M | 42.01M | 39.55M | 37.87M | 44.52M |
| Cost of Revenue | 8.81M | 9.12M | 6.07M | 6.59M | 6.67M |
| Gross Profit | 27.17M | 32.89M | 33.49M | 31.28M | 37.85M |
| Gross Margin | 75.5% | 78.3% | 84.7% | 82.6% | 85.0% |
| Research & Development | 5.68M | 6.69M | 5.83M | 4.82M | 5.57M |
| Selling, General & Admin | 24.8M | 26.84M | 29.1M | 28.15M | 31.05M |
| Operating Expenses | 34.85M | 38.6M | 43.04M | 37.71M | 40.65M |
| Depreciation & Amortization | 4.61M | 5.33M | 8.1M | 6.04M | 5.29M |
| EBITDA | (857.83K) | 332.92K | 2.49M | 182.42K | 2.96M |
| EBITDA Margin | -2.4% | 0.8% | 6.3% | 0.5% | 6.6% |
| Operating Income | (7.68M) | (5.7M) | (9.55M) | (6.43M) | (2.79M) |
| Operating Margin | -21.3% | -13.6% | -24.2% | -17.0% | -6.3% |
| Interest Income | 26.08K | 98.41K | 286.85K | 334.44K | 476.75K |
| Interest Expense | 98.03K | 586K | 667.86K | 605.51K | 495.99K |
| Other Income / Expenses | 2.12M | 123.74K | 3.27M | (33.98K) | (32.46K) |
| Income Before Tax | (5.56M) | (5.58M) | (6.28M) | (6.47M) | (2.82M) |
| Pre-Tax Margin | -15.5% | -13.3% | -15.9% | -17.1% | -6.3% |
| Income Tax Expense | 34.89K | 68.85K | 45.77K | (22.67K) | 40.26K |
| Net Income | (3.51M) | (5.57M) | (6.28M) | (6.48M) | (2.84M) |
| Net Margin | -9.7% | -13.3% | -15.9% | -17.1% | -6.4% |
| EPS (Basic) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| EPS (Diluted) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| Weighted Avg Shares | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
| Weighted Avg Shares (Diluted) | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.